Aclara to provide eTag to Glaxo

Aug. 1, 2003 — Aclara BioSciences is providing products and services to GlaxoSmithKline plc (GSK) for drug discovery and development programs, according to a news release.

Mountain View, Calif.-based Aclara, which has signed similar deals with several pharmaceutical companies, will provide its microfluidic eTag Assay System to London-based GSK. Aclara said its system enables accurate analysis of genes and proteins from limited biological samples and can be used with researchers’ existing equipment.

Aclara, listed on the Nasdaq, closed Thursday at 4.00, up from 3.60 Wednesday. GSK, listed on the NYSE, closed Thursday at 38.31, down from 39.22 Wednesday.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.